Farmacologiay Toxicologia©
2 (13) 2023 : 001-002 • Editorial Article

Designing Drug Compositions for Improved Therapeutic Outcomes: A Review of Current Strategies

Ujvyid Tanyehi*

Department of Industrial and Systems Engineering, North Carolina State University, Raleigh, NC 27606, USA

AUTHORS' CONTRIBUTION: (A) Study Design · **(B)** Data Collection . **(C)** Statistical Analysis · **(D)** Data Interpretation · **(E)** Manuscript Preparation · **(F)** Literature Search · **(G)** No Fund Collection

ABSTRACT

The development of new drugs and drug combinations is a constantly evolving process aimed at improving the efficacy and safety of therapies for a variety of diseases. In this review, we discuss the current strategies used in designing drug compositions to enhance therapeutic outcomes. We provide an overview of the principles of drug combination therapy and explore the advantages and challenges of different approaches, including fixed-dose combinations, sequential administration, and co-drug delivery. We also examine recent advances in drug design that allow for more precise control of drug release and delivery, such as nanotechnology and targeted drug delivery systems. Finally, we discuss the importance of considering drug-drug interactions and the potential for adverse effects when designing drug compositions. Overall, the review highlights the need for continued research and development in drug composition design to improve patient outcomes and address the challenges of complex diseases

Keywords: Drug composition; Combination therapy; Fixed-dose combinations; Sequential administration; Co-drug delivery; Nanotechnology; Targeted drug delivery; Drug-drug interactions

Address for correspondence:

Dr. Ujvyid Tanyehi,
Department of Industrial and Systems Engineering, North Carolina State University, Raleigh, NC 27606, USA
E-mail: U_Tanyehi@gmail.com

Word count: 1040 **Tables:** 00 **Figures:** 00 **References:** 10

Received: 03.04.2023, Manuscript No. ipft-23- ipft-23-13754; **Editor assigned:** 05.04.2023, PreQC No. P-13754; **Reviewed:** 19.04.2023, QC No. Q-13754; **Revised:** 22.04.2023, Manuscript No. R-13754; **Published:** 29.04.2023

INTRODUCTION

The treatment of complex diseases often requires the use of multiple drugs with different mechanisms of action to achieve optimal therapeutic outcomes. Combination therapy, the use of two or more drugs simultaneously, is an effective approach to treat such diseases. The concept of combination therapy is not new, and has been used for decades to treat various diseases such as HIV, cancer, and tuberculosis. The idea is to use drugs that act on different targets or pathways, thereby increasing the likelihood of achieving a better clinical response and reducing the risk of drug resistance. However, designing drug compositions for optimal therapeutic outcomes remains a challenge, and requires a thorough understanding of drug pharmacology, pharmacokinetics, and drug-drug interactions [1, 2]

DISCUSSION

Fixed-dose Combinations

Fixed-dose combinations (FDCs) are the most common approach to combination therapy. FDCs are formulations that contain two or more drugs in fixed ratios, which are administered together as a single tablet or capsule. FDCs offer several advantages over individual drug administration, including increased patient compliance and reduced risk of dosing errors. They can also simplify the dosing regimen, reduce costs, and improve treatment outcomes by targeting multiple pathways. FDCs have been used to treat a range of diseases, including hypertension, diabetes, tuberculosis, and HIV [3, 4].

However, designing FDCs requires careful consideration of drug pharmacology and pharmacokinetics. The drugs must be compatible with each other and remain stable in the formulation. Additionally, the dosing ratio must be carefully selected to achieve the desired therapeutic effect without increasing the risk of adverse events. Some drugs may have overlapping toxicities, and combining them may increase the risk of adverse events. For example, FDCs containing no steroidal anti-inflammatory drugs (NSAIDs) and acetaminophen have been associated with increased risk of liver and kidney damage [5, 6].

Sequential Administration

Sequential administration is another approach to combination therapy. This involves administering drugs in a specific sequence or schedule to achieve optimal therapeutic outcomes. The idea is to use drugs that target different stages of the disease process, such as induction,

consolidation, and maintenance. Sequential administration can also be used to minimize drug-drug interactions and reduce toxicity by avoiding the concurrent administration of drugs that have overlapping toxicities [7].

One example of sequential administration is the use of preoperative chemotherapy followed by surgery for the treatment of breast cancer. In this approach, chemotherapy is used to shrink the tumor before surgery, which can improve surgical outcomes and reduce the risk of recurrence. Similarly, in the treatment of tuberculosis, a combination of drugs is administered in a specific sequence to achieve optimal therapeutic outcomes[8].

Co-drug Delivery

Co-drug delivery is a more recent approach to combination therapy that involves the use of pro-drugs, which are inactive or minimally active drug derivatives that are designed to be converted to the active drug in vivo. Co-drug delivery involves the administration of two or more pro-drugs that are designed to undergo conversion to the active drugs in a specific sequence or location. This approach allows for more precise control of drug release and delivery, which can improve efficacy and reduce toxicity [9].

Nanotechnology and targeted drug delivery

Recent advances in drug design have focused on the use of nanotechnology and targeted drug delivery systems to improve drug efficacy and reduce toxicity. Nanoparticles, such as liposomes, polymeric nanoparticles, and dendrites, have been used to improve drug solubility and stability, as well as to target specific tissues or cells. Targeted drug delivery systems can be designed to release drugs in response to specific stimuli, such as changes in pH, temperature, or enzyme activity.

Considerations for drug composition design

When designing drug compositions, it is important to consider the potential for drug-drug interactions and adverse effects. Drug interactions can occur when two or more drugs are administered together, leading to changes in drug pharmacokinetics or pharmacodynamics. Adverse effects can also occur when drugs with overlapping toxicities are combined. In some cases, the benefits of combination therapy may outweigh the risks of drug interactions or adverse effects. However, careful consideration of these factors is necessary to ensure patient safety and improve therapeutic outcomes [10].

CONCLUSION

The development of drug compositions for improved therapeutic outcomes is an ongoing process that requires a thorough understanding of drug pharmacology, pharmacokinetics, and drug-drug interactions. Fixed-dose combinations, sequential administration, co-drug delivery, and targeted drug delivery systems are all approaches that can be used to achieve optimal therapeutic outcomes. Advances in nanotechnology and drug design have opened up new possibilities for more precise control of drug release and delivery. However, careful consideration of drug-drug interactions and adverse effects is necessary to ensure patient safety and improve treatment outcomes. Continued research and development in drug composition design is necessary to address the challenges of complex diseases and improve patient outcomes.

ACKNOWLEDGMENT

None

CONFLICT OF INTEREST

No conflict of interest to declare about this work.

REFERENCES

1. **Zadik Yehuda, Aktaş Alper, Drucker Scott.** Aneurysmal bone cyst of mandibular condyle: A case report and review of the literature. *J Craniomaxillofac Surg*.2012; 40(6): 243-248.
2. **Ye Y, Pringle LM, Lau AW.** TRE17/USP6 oncogene translocated in aneurysmal bone cyst induces matrix metalloproteinase production via activation of NF-kappaB. *Oncogene*.2010; 29(2): 3619-3629.
3. **Mankin HJ, Hornicek FJ, Ortiz-Cruz E et al.** (2005) Aneurysmal bone cyst: a review of 150 patients. *J Clin Oncol*.2005; 23(1): 6756-6762.
4. **Amanatullah DF, Clark TR, Lopez MJ, et al.** (2014) Giant Cell Tumor of Bone. *Orthopedics*.2014; 37(5): 112-120.
5. **Baig R, Eady J.** unicameral (simple) bone cysts. *Southern Medical Journal* .2005; 99(4): 966-976.
6. **Milbrandt, Todd; Hopkins, Jeffrey.** (2007) unicameral bone cysts: etiology and treatment. *Curr Opin Orthop.* 2007; 18(6): 555-560.
7. **Rapp Timothy B, Ward James P, Alaia Michael J.** Aneurysmal Bone Cyst. *J Am Acad Orthop Surg*.2012; 20 (5): 233-241.
8. **Ozyurek Selahattin, Rodop Osman, Kose Ozkan, et al.** (2009) Aneurysmal Bone Cyst of the Fifth Metacarpal. *Orthopedics.* 2009; 32(5): 606-609.
9. **Rodrigues CD, Estrela Carlos** (2008) Traumatic Bone Cyst Suggestive of Large Apical Periodontitis. *Journal of Endodontics*.2008; 34(6): 484-489.
10. **Bloodgood, Joseph C.** Benign Bone Cysts, Ostitis Fibrosa, Giant-Cell Sarcoma and Bone Aneurism of the Long Pipe Bones. *Annals of Surgery*.2011; 52(2): 145-185.